Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Editas Medicine's gross profit for the
three
months ended in Jun. 2026 was $11.89 Mil. Editas Medicine's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $47.01 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Editas Medicine's gross profit for the
three
months ended in Jun. 2026 was $11.89 Mil. Editas Medicine's Revenue for the
three
months ended in Jun. 2026 was $11.89 Mil. Therefore, Editas Medicine's Gross Margin % for the quarter that ended in Jun. 2026 was N/A%.
Editas Medicine had a gross margin of N/A% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Editas Medicine (NAS:EDIT) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Editas Medicine had a gross margin of N/A% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Editas Medicine Gross Profit Related Terms
Editas Medicine Gross Profit Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Editas Medicine's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Gross Profit distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.01 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Editas Medicine (EDIT) has a Gross Profit of $47.01 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's Gross Profit too high?
Editas Medicine's current Gross Profit is $47.01 Mil. Overall, Editas Medicine has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Gross Profit compare to BNTC and PBYI?
Editas Medicine's Gross Profit of $47.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Editas Medicine and its competitors. Editas Medicine's current Gross Profit is $47.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.11 — trading 36.4% above its estimated fair value. The current Gross Profit is $47.01 Mil. Editas Medicine's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Gross Profit is $47.01 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.11 is trading 36.4% above its estimated GF Value™ of $2.28.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Gross Profit: $47.01 Mil
GF Value™: $2.28 vs. price of $3.11 (36.4% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
57GF Score
Get the complete analysis for EDIT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
